69 Results for "

dyskinesia

" in MedChemExpress (MCE) Product Catalog:
Products (69)

69 Results for "dyskinesia" in MCE Product Catalog:

5
5 Cited Publications
Cat. No.: HY-B1744
CAS No.: 54-47-7
Synonyms: Pyridoxal 5′-phosphate; Pyridoxyl phosphate
Pyridoxal phosphate is the active form of vitamin B6, acts as an inhibitor of reverse transcriptases, and is used for the treatment of tardive dyskinesia.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-15257
CAS No.: 543906-09-8
Purity:  99.88%
Synonyms: AFQ056
Target:  

mGluR

Research Areas:  

Neurological Disease

Mavoglurant (AFQ056) is a potent, selective, non-competitive and orally active mGluR5 antagonist, with an IC50 of 30 nM. Mavoglurant shows a >300 fold selectivity for the mGluR5 over all targets (238) tested. Mavoglurant can be used for the research of Fragile X syndrome (FXS), and L-dopa induced dyskinesias in Parkinson's disease . Mavoglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-B1752
CAS No.: 80373-22-4
Synonyms: LY 171555; (-)-LY 141865
Quinpirole (LY 171555; (-)-LY 141865) is a D2/D3 dopamine receptor agonist and a CaV1.3 calcium channel modulator. Quinpirole normalizes dendritic spine density in dopamine-depleted striatum, upregulates the protein expression of BCL2 and GluR2, downregulates the protein expression of BAX, and delays the onset of seizures. Quinpirole enhances learning and memory, inhibits neuronal apoptosis (apoptosis), and induces anxiety-like, stereotyped, and compulsive behaviors. Quinpirole disrupts prepulse inhibition in rhesus monkeys, enhances the activity of paraventricular thalamic neurons to promote recovery from Isoflurane anesthesia, and alters the composition of the gut microbiota in rats. Quinpirole can be used in research related to dyskinesia, pain, epilepsy, and neurological disorders including anxiety disorder, obsessive-compulsive disorder, and schizophrenia .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P1335
CAS No.: 103429-32-9
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P1335A
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-Y1089
CAS No.: 1122-58-3
4-Dimethylaminopyridine is an acyl transfer catalyst. 4-Dimethylaminopyridine is used for labeling and analysis of glycoproteins on the surface of living cells. 4-Dimethylaminopyridine reduces dyskinesia attacks .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0590
CAS No.: 58-46-8
Synonyms: Ro 1-9569
Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 Ki 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-12707
CAS No.: 3605-01-4
Purity:  99.33%
Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18654
CAS No.: 1235318-89-4
Target:  

mGluR

Research Areas:  

Neurological Disease

ADX88178 is an orally active, blood-brain barrier-penetrant, selective positive allosteric modulator of mGluR4, with an EC50 of 3.5 nM against hmGluR4. ADX88178 modulates mGlu4 activity, enhances glutamate-mediated receptor activation, and increases the apparent affinity of glutamate for the receptor. ADX88178 reverses haloperidol-induced catalepsy, potentiates the effects of levodopa (L-DOPA) and quinpirole, but fails to alleviate established abnormal involuntary movements, does not exacerbate L-DOPA-induced dyskinesia, and does not affect forelimb akinesia when administered alone. ADX88178 can be used in research related to L-DOPA-induced dyskinesia and Parkinson's disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-100820
CAS No.: 351862-32-3
Purity:  98.74%
Synonyms: EMD 128130
Research Areas:  

Neurological Disease

Sarizotan (EMD 128130) is an orally active serotonin 5-HT1A receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC50 values of 6.5 nM (rat 5-HT1A), 0.1 nM (human 5-HT1A), 15.1 nM (rat D2), 17 nM (human D2), 6.8 nM (human D3) and 2.4 nM (human D4.2), respectively .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-119093
CAS No.: 59831-65-1
Purity:  99.65%
Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent .
loading...
    loading...
Cat. No.: HY-B0590S
CAS No.: 1392826-25-3
Synonyms: Ro 1-9569-d6
Tetrabenazine-d6 (Deutetrabenazine) is a deuterium-labled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 Ki 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .
loading...
    loading...
Cat. No.: HY-162666
CAS No.: 3038770-25-8
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

TMEM175 modulator 1 (compound 47) is a TMEM175 modulator.TMEM175 modulator 1 modulates activity of the lysosomal potassium ion channel TMEM175.TMEM175 modulator 1 can be used for the research of parkinson’s disease, dementia, alzheimer’s disease, l-dopa induced dyskinesia .
loading...
    loading...
Cat. No.: HY-14859
CAS No.: 872363-17-2
Purity:  99.90%
Synonyms: ADX48621
Target:  

mGluR

Research Areas:  

Neurological Disease

Dipraglurant (ADX48621) is a potent, selective, orally active and brain penetrant mGluR5 negative allosteric modulator (NAM), with an IC50 of 21 nM. Dipraglurant can reduce Levodopa-induced dyskinesia (LID) in vivo . Dipraglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-14561A
CAS No.: 79944-56-2
Purity:  99.32%
Synonyms: RX 781094 hydrochloride
Idazoxan hydrochloride (RX 781094 hydrochloride) is an α2-adrenoceptor antagonist and is also a imidazoline receptors (IRs) antagonist competitively antagonized the centrally induced hypotensive effect of imidazoline-like agents (IMs). Idazoxan hydrochloride also improves motor symptoms in Parkinson’s disease, L-DOPA-induced dyskinesias, and experimental Parkinsonism .
loading...
    loading...
Cat. No.: HY-B1904
CAS No.: 5002-47-1
Target:  

Dopamine Receptor

Research Areas:  

Neurological Disease

Fluphenazine decanoate is a CNS-penetrant dopamine D2 receptor inhibitor, is a long-acting phenothiazine neuroleptic. Fluphenazine can be used for schizophrenia research .
loading...
    loading...
Cat. No.: HY-B1744R
CAS No.: 54-47-7
Synonyms: Pyridoxal 5′-phosphate (Standard); Pyridoxyl phosphate (Standard)
Pyridoxal phosphate (Standard) is the analytical standard of Pyridoxal phosphate. This product is intended for research and analytical applications. Pyridoxal phosphate is the active form of vitamin B6, acts as an inhibitor of reverse transcriptases, and is used for the treatment of tardive dyskinesia.
loading...
    loading...
Cat. No.: HY-131678
CAS No.: 212707-51-2
Purity:  ≥99.0%
Synonyms: PA-5HT
Target:  

FAAH

Research Areas:  

Neurological Disease

Palmitoyl serotonin is a hybrid molecule patterned after arachidonoyl serotonin, antagonist of FAAH. Palmitoyl serotonin inhibits L-3,4-dihydroxyphenylalanine (HY-N0304) induced abnormal involuntary movements. Palmitoyl serotonin has the potential for the research of parkinson's disease (PD) .
loading...
    loading...
Cat. No.: HY-B0590A
CAS No.: 718635-93-9
Synonyms: Ro 1-9569 Racemate
Tetrabenazine (Ro 1-9569) Racemate is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 Ki 100 nM. Tetrabenazine Racemate binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine Racemate weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine Racemate can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .
loading...
    loading...
Cat. No.: HY-W152604
CAS No.: 5845-67-0
Synonyms: Cyclo(leu-gly)
Target:  

Dopamine Receptor

Research Areas:  

Neurological Disease

Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates dopamine (DA) receptors and attenuates dopaminergic supersensitivity. Cyclo(glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo(glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304)-induced dyskinesias .
loading...
    loading...